Graham J, Mcbride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, Griffiths M, Agirrezabal I, Zuberbier T, Brennan A. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics. 2016 Aug;34(8):815-27. doi: 10.1007/s40273-016-0412-1